Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses
Summary: Antibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset of patients remains refractory to ADC treatment, suggesting that the efficacy requires further optimization. H...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Elsevier
2025-03-01
|
| 叢編: | iScience |
| 主題: | |
| 在線閱讀: | http://www.sciencedirect.com/science/article/pii/S2589004224027639 |